However, like the other AMPs, DCD-derived peptides can promote epidermal inflammation via TNF-α, IL-8, CXCL 10 and CCL20 (102), limiting the opportunity for therapeutic targeting of DCD in HS. Here, TNF is linked to histiocytic sarcoma.